Analysis supports long-term safety of nintedanib in treatment of systemic sclerosis-associated interstitial lung disease

Analysis of SENSCIS-ON extension study found safety profile of nintedanib in subjects who continued therapy for an additional 52 weeks was consistent with that observed during SENSCIS trial. Furthermore, 44% of subjects maintained, and 22% had an improvement in baseline FVC.

Source:

Biospace Inc.